Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research note ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

Valneva (NASDAQ:VALN – Free Report) had its price target cut by HC Wainwright from $19.00 to $18.00 in a report released on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Great hopes rest on a product from the French-Austrian company Valneva. However, a vaccine from U.S. company Novavax, also based on proven technology, may reach more markets this winter.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

VALNEVA Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and ...